PH12014500943A1 - Combination treatment of cancer - Google Patents
Combination treatment of cancerInfo
- Publication number
- PH12014500943A1 PH12014500943A1 PH1/2014/500943A PH12014500943A PH12014500943A1 PH 12014500943 A1 PH12014500943 A1 PH 12014500943A1 PH 12014500943 A PH12014500943 A PH 12014500943A PH 12014500943 A1 PH12014500943 A1 PH 12014500943A1
- Authority
- PH
- Philippines
- Prior art keywords
- cancer
- relates
- treatment
- combinations
- pharmaceutically acceptable
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000011284 combination treatment Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 229960004671 enzalutamide Drugs 0.000 abstract 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 abstract 1
- JMEYDSHPKCSIJC-UHFFFAOYSA-N 1-[4-[2-[4-[1-[3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CCOC1=CC=C(C2CCN(CC2)C=2CCC=3N(C(=NN=3)C(F)(F)F)N=2)C=C1 JMEYDSHPKCSIJC-UHFFFAOYSA-N 0.000 abstract 1
- 229960000853 abiraterone Drugs 0.000 abstract 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 abstract 1
- 229960004103 abiraterone acetate Drugs 0.000 abstract 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 abstract 1
- 229960000997 bicalutamide Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564975P | 2011-11-30 | 2011-11-30 | |
| PCT/GB2012/052969 WO2013079964A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014500943A1 true PH12014500943A1 (en) | 2014-06-30 |
Family
ID=47295082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2014/500943A PH12014500943A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20140329786A1 (enExample) |
| EP (1) | EP2785349B2 (enExample) |
| JP (1) | JP6309454B2 (enExample) |
| KR (1) | KR102035361B1 (enExample) |
| CN (1) | CN103945849B (enExample) |
| AU (2) | AU2012321110B2 (enExample) |
| CA (1) | CA2856646C (enExample) |
| CY (1) | CY1122624T1 (enExample) |
| DK (1) | DK2785349T4 (enExample) |
| ES (1) | ES2762250T5 (enExample) |
| FI (1) | FI2785349T4 (enExample) |
| HR (1) | HRP20191982T4 (enExample) |
| HU (1) | HUE046667T2 (enExample) |
| IL (1) | IL232530B (enExample) |
| LT (1) | LT2785349T (enExample) |
| MX (1) | MX367640B (enExample) |
| MY (1) | MY175800A (enExample) |
| PH (1) | PH12014500943A1 (enExample) |
| PL (1) | PL2785349T5 (enExample) |
| PT (1) | PT2785349T (enExample) |
| RS (1) | RS59493B2 (enExample) |
| RU (1) | RU2640485C2 (enExample) |
| SG (1) | SG11201401471PA (enExample) |
| SI (1) | SI2785349T2 (enExample) |
| SM (1) | SMT201900708T1 (enExample) |
| WO (1) | WO2013079964A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| BRPI0920465A2 (pt) | 2008-10-02 | 2018-03-20 | Salix Pharmaceuticals, Inc. | metodo de tratamento de encefalopatia hepática |
| EP2393827B1 (en) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| BR112013017722A2 (pt) | 2011-01-11 | 2016-07-12 | Glaxosmithkline Llc | combinação |
| AU2012358219A1 (en) * | 2011-12-22 | 2014-07-10 | Tokai Pharmaceuticals, Inc. | Methods and compositions for combination therapy using P13K/mTOR inhibitors |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| EP2945628B1 (en) | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| KR20160058774A (ko) | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| MX2016004267A (es) * | 2013-10-01 | 2016-07-08 | Novartis Ag | Combinacion. |
| CA2923899A1 (en) * | 2013-10-01 | 2015-04-09 | Novartis Ag | Enzalutamide in combination with afuresertib for the treatment of cancer |
| WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| WO2018015958A1 (en) | 2016-07-21 | 2018-01-25 | Hadasit Medical Research Services And Development Ltd. | Ar antagonists or inhibitors for use in treating glioblastoma |
| KR20220028178A (ko) * | 2016-12-16 | 2022-03-08 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
| CN107670048B (zh) * | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| MA50189A (fr) * | 2017-09-22 | 2021-05-19 | Dispersol Technologies Llc | Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| CN108486041A (zh) * | 2018-03-28 | 2018-09-04 | 华南农业大学 | PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法 |
| CN114026106B (zh) | 2019-03-06 | 2025-01-21 | 普洛拉治疗公司 | 阿比特龙前药 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (enExample) | 1963-04-04 | 1900-01-01 | ||
| DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
| ES2138618T3 (es) | 1992-03-31 | 2000-01-16 | Btg Int Ltd | Esteroides 17-sustituidos utiles en el tratamiento del cancer. |
| WO1999000113A1 (en) | 1997-06-27 | 1999-01-07 | Vivorx Pharmaceuticals, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| WO1999007703A1 (en) | 1997-08-05 | 1999-02-18 | Pfizer Products Inc. | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU4231299A (en) | 1998-06-04 | 1999-12-20 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| OA12292A (en) | 2000-06-26 | 2003-11-11 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents. |
| KR100602929B1 (ko) | 2000-08-31 | 2006-07-20 | 에프. 호프만-라 로슈 아게 | 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체 |
| BR0115847A (pt) | 2000-12-01 | 2004-02-25 | Osi Pharm Inc | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| UY27220A1 (es) | 2001-03-23 | 2002-09-30 | Aventis Pharma Sa | Combinación de un taxano con una quinasa ciclina-dependiente |
| DE60305446T4 (de) | 2002-01-07 | 2009-07-09 | Eisai R&D Management Co., Ltd. | Desazapurine und deren verwendung |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| NZ535992A (en) | 2002-05-17 | 2008-11-28 | Aventis Pharma Sa | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
| DK1522314T3 (da) | 2002-06-26 | 2014-05-26 | Ono Pharmaceutical Co | Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| US20060159617A1 (en) | 2002-11-08 | 2006-07-20 | Ashfaq Mahmood | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
| AU2003302657B8 (en) | 2002-12-04 | 2009-12-03 | Eisai R&D Management Co., Ltd. | Fused 1,3-dihydroimidazole ring compounds |
| US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
| EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
| MXPA05009722A (es) | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
| AU2004232392A1 (en) | 2003-04-21 | 2004-11-04 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (Purin-6-yl) amino acid and production method thereof |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| AU2004293026B2 (en) | 2003-11-21 | 2012-01-19 | Array Biopharma Inc. | AKT protein kinase inhibitors |
| WO2005063704A1 (ja) | 2003-12-25 | 2005-07-14 | Ono Pharmaceutical Co., Ltd. | アゼチジン環化合物およびその医薬 |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| AU2005322085B2 (en) | 2004-12-28 | 2012-07-19 | Exelixis, Inc. | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
| FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
| US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| WO2006090129A2 (en) * | 2005-02-23 | 2006-08-31 | Astrazeneca Ab | Bicalutamide for delivering increasing steady state plasma levels |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| JP5071374B2 (ja) | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ３阻害剤 |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP2009534456A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| US20090253718A1 (en) | 2006-04-25 | 2009-10-08 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| WO2008079346A1 (en) | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| BRPI0818533B8 (pt) * | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| EP2393827B1 (en) * | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| WO2010092371A1 (en) * | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
| WO2011029782A1 (en) * | 2009-09-11 | 2011-03-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
| CA2798074A1 (en) * | 2010-04-27 | 2011-11-03 | The Johns Hopkins University | Immunogenic compositions and methods for treating neoplasia |
-
2012
- 2012-11-30 MX MX2014006547A patent/MX367640B/es active IP Right Grant
- 2012-11-30 FI FIEP12795842.9T patent/FI2785349T4/fi active
- 2012-11-30 DK DK12795842.9T patent/DK2785349T4/da active
- 2012-11-30 RS RS20191392A patent/RS59493B2/sr unknown
- 2012-11-30 KR KR1020147016680A patent/KR102035361B1/ko active Active
- 2012-11-30 WO PCT/GB2012/052969 patent/WO2013079964A1/en not_active Ceased
- 2012-11-30 SI SI201231690T patent/SI2785349T2/sl unknown
- 2012-11-30 HR HRP20191982TT patent/HRP20191982T4/hr unknown
- 2012-11-30 SM SM20190708T patent/SMT201900708T1/it unknown
- 2012-11-30 LT LT12795842T patent/LT2785349T/lt unknown
- 2012-11-30 HU HUE12795842A patent/HUE046667T2/hu unknown
- 2012-11-30 SG SG11201401471PA patent/SG11201401471PA/en unknown
- 2012-11-30 ES ES12795842T patent/ES2762250T5/es active Active
- 2012-11-30 CA CA2856646A patent/CA2856646C/en active Active
- 2012-11-30 AU AU2012321110A patent/AU2012321110B2/en active Active
- 2012-11-30 PH PH1/2014/500943A patent/PH12014500943A1/en unknown
- 2012-11-30 US US14/361,718 patent/US20140329786A1/en not_active Abandoned
- 2012-11-30 CN CN201280059109.1A patent/CN103945849B/zh active Active
- 2012-11-30 PL PL12795842.9T patent/PL2785349T5/pl unknown
- 2012-11-30 PT PT127958429T patent/PT2785349T/pt unknown
- 2012-11-30 MY MYPI2014701394A patent/MY175800A/en unknown
- 2012-11-30 EP EP12795842.9A patent/EP2785349B2/en active Active
- 2012-11-30 JP JP2014543977A patent/JP6309454B2/ja active Active
- 2012-11-30 AU AU2013205648A patent/AU2013205648B2/en active Active
- 2012-11-30 RU RU2014119713A patent/RU2640485C2/ru active
-
2014
- 2014-05-08 IL IL232530A patent/IL232530B/en active IP Right Grant
-
2016
- 2016-02-08 US US15/018,157 patent/US9737540B2/en active Active
-
2019
- 2019-12-17 CY CY20191101323T patent/CY1122624T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY175800A (en) | Combination treatment of cancer | |
| GB201118656D0 (en) | New compounds | |
| PH12013500955A1 (en) | Spiro-oxindole mdm2 antagonists | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| MX346224B (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
| MX349004B (es) | Nuevos compuestos. | |
| TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
| WO2012112410A3 (en) | Micronized placental tissue compositions and methods for making and using the same | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| MX366899B (es) | Nuevos compuestos. | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| IN2015DN01119A (enExample) | ||
| MY162397A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| PH12013501591A1 (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| MX361349B (es) | Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas. | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| IN2014DN03010A (enExample) | ||
| MX2015011588A (es) | Tratamiento de combinacion. | |
| MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
| EP2785335B8 (en) | Methods and pharmaceutical compositions for the treatment of darier disease | |
| WO2014015137A3 (en) | Compositions and methods for treating dysproliferative diseases |